Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.
Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.
在 Biogen 和 Elsai 宣布 Leanemab 治療其主要終點並減少了全球認知和功能規模的臨床下降之後,擁有阿爾茨海默氏症計劃的公司的股票正在交易。
Shares of companies with Alzheimer's programs are trading after Biogen and Elsai announced Lecanemab treatment its the primary endpoint and reduced clinical decline on the global cognitive and functional scale.
在 Biogen 和 Elsai 宣布 Leanemab 治療其主要終點並減少了全球認知和功能規模的臨床下降之後,擁有阿爾茨海默氏症計劃的公司的股票正在交易。